treatment

Aristoteles Giagounidis is Head of the Department of Oncology, Haematology, and Palliative Care at Marien Hospital in Düsseldorf, Germany. After earning his medical degree in 1992 from Eberhard-Karls-University in Tübingen, Germany, Dr Giagounidis was house officer at the Withybush General Hospital in Haverfordwest, Wales, and at the William Harvey Hospital in Ashford, Kent, UK. He then served as resident physician at the Haematology/Oncology Department of Heinrich-Heine- University in Düsseldorf, where he became board certified in 1999. Due to his special expertise in haematological cytology

Amer Zeidan’s primary research interest is in myelodysplastic syndromes (MDS) and was mentored in this research area by Dr. Steven Gore and Dr. B Douglas Smith at Johns Hopkins University where he has completed a clinical hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes. He also earned a Master of Health Science (MHS) degree in Clinical Investigation at Johns Hopkins before recently moving to Yale University as an Assistant Professor of Medicine to reunite with Dr. Steven Gore and continue his MDS research. Dr. Zeidan has two major areas of

Valeria Santini is an Associate Professor of Hematology at the University of Florence Medical School in Florence Italy, where she received her degree in Medicine and Postgraduate diploma in hematology (cum laude). She worked as an EORTC fellow in experimental hematology from 1988 to 1991 at the Dr. den Hoed Kliniek, Erasmus University, Rotterdam. In 1999 she worked in the Department of Leukemia at MD Anderson Cancer Center, University of Texas, Houston. Her scientific interests and publications are focused on maturation induction and therapeutic targeting of epigenetics modifications, myeloid

Dr. Graubert’s research focuses on the molecular pathogenesis of myeloid leukemias. While at Washington University in St. Louis, he and his colleagues used genome sequencing technology extensively to gain insights into the genetic basis of human cancer and to use this information to improve risk stratification tools and identify targets for novel therapy. Their group published the first complete genome sequence of a human cancer (acute myeloid leukemia) in 2008 and in subsequent publications described novel recurrent mutations in IDH2 and DNMT3A that have prognostic significance in acute

Dr. Amy DeZern is a hematologist and medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and is an Assistant Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine. She received her medical degree in 2005 from the Johns Hopkins University School of Medicine and her Master in Clinical Investigation (M.H.S.) from the Johns Hopkins Bloomberg School of Public Health. She completed residency training in internal medicine as well as fellowships in medical oncology and hematology at Johns Hopkins. Dr. DeZern sees patients at the Sidney Kimmel

Dr. Rossetti earned his Doctor of Osteopathic Medicine degree from the Lake Erie College of Osteopathic Medicine and completed an internship and internal medicine residency at St. Francis Medical Center of Pittsburgh. He did fellowship training in hematology and medical oncology at The Western Pennsylvania Hospital and is board certified in medical oncology and hematology. He is an assistant professor at the Temple University School of Medicine and an adjunct clinical instructor for the Lake Erie College of Osteopathic Medicine. Dr. Rossetti is a recognized expert in hematological malignancy